Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trimetrexate glucuronate
- Development stage
- Phase 3
- Lead developer
- U.S. Bioscience
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Trimetrexate glucuronate is a synthetic non-classical folate antagonist that inhibits the enzyme dihydrofolate reductase (DHFR). It is primarily used for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, particularly those with AIDS. Due to its potentially serious toxicities, it must be administered with concurrent leucovorin (leucovorin protection) to prevent life-threatening side effects.
- Brand names
- Neutrexin
- Other names
- CI 898CI898CI-898
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on trimetrexate glucuronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trimetrexate glucuronate.